novo nordisk weight loss drug

Novo Nordisk Shares Fall

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Reuters · 2d

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Investopedia on MSN · 3d

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

Novo Nordisk Skeptic Finally Upgrades Stock

The Motley Fool on MSN · 1d

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 10.22%) and Roche Holdings ( RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it.

Bloomberg L.P. · 15h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Business Insider · 20h

Novo Nordisk upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s

1don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Compound versions of some weight loss drugs to be restricted

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

US FDA to hold off action on weight-loss drug copies pending court ruling

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results